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A study on the management  
of corticosteroid side effects  
in cancer patients 
abstraCt
background
Systemic corticosteroids lead to many adverse effects 
especially in cancer patients. Preventive measures and 
treatment options are essential to minimise such side 
effects. 
objectives
The aims of the study included the evaluation 
of the prescribers’ management of corticosteroid 
induced hyperglycaemia, dyspepsia, oral candidiasis 
and proximal myopathy, the discussion of possible 
reasons for non-adherence to guidelines, and the 
recommendation of interventions to reduce their risk 
of occurrence.
Method
A retrospective review of the medical records for 156 
consecutive patients at oncology out-patients and in 
oncology wards of Boffa Hospital between the 1st and the 
14th September 2014 was performed. Only patients who 
were on long term corticosteroids (>2 weeks’ duration) 
were considered. Patients younger than 12 years of 
age or those that were prescribed corticosteroids for 
antiemetic purposes were excluded from the study. For 
each of the sampled patients, any management aimed 
at reducing corticosteroid side effects was compared 
to the guidelines as stated in an article published in a 
prominent international journal.
results
From 156 cancer patients, 55 patients satisfied 
the inclusion criteria. The mostly addressed side 
effect was dyspepsia (n=35; 63.6%) followed by 
proximal myopathy (n=27; 49%), hyperglycaemia 
(n=24; 43.6%) and lastly oral candidiasis (n=20; 
36%). Adherence to guidelines was as follows: 
hyperglycaemia – haemo-glucose test (HGT) and 
glycated haemoglobin (HbA1c) (36%); dyspepsia - 
prescribing of omeprazole (51%) and ranitidine (5%); 
oral candidiasis - orophargyngeal exam (29%); and 
proximal myopathy (40% compliance; of which 35% 
complying with resistance and endurance exercise 
and 5% complying with steroid dose reduction).
Conclusion
Improvement is required with regards to the 
management of corticosteroid side effects especially 
for hyperglycaemia and oral candidiasis. Possible 
actions that may be taken include strategies to 
improve guideline awareness, the prescribing of the 
lowest effective dose, adequate patient education and 
the implementation of a steroid card.
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introDuCtion
Corticosteroids have many indications for use in 
palliative care and oncology, primarily owing to their 
anti-inflammatory properties (Lussier et al., 2004). 
Despite their beneficial effects, long term 
systemic (oral or parenteral) use of these agents is 
associated with well known adverse events mainly 
hyperglycaemia, dyspepsia, oral candidiasis and 
proximal myopathy.
It is therefore the role of the clinician to minimize 
the risk of such side effects through appropriate 
active and proactive management, especially in 
debilitating patients such as cancer patients. 
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The main aims of the study include:
•	 To evaluate the prescribers’ management of 
corticosteroid side effects, specifically for 
hyperglycaemia, dyspepsia, oral candidiasis and 
proximal myopathy;
•	 To discuss possible reasons for non-adherence to 
guidelines; and
•	 To recommend possible interventions to reduce 
their risk of occurrence.
All this should make the prescriber more aware of 
corticosteroid side effects in cancer patients as well as 
providing him with a variety of options for optimally 
addressing or preventing the manifestation of adverse 
effects.
For a better understanding of the study, the term 
“management” will be used to refer to either or both 
clinical management and pro-active approach. On the other 
hand “addressing” a side effect will include one or all of 
clinical assessment, clinical education, and treatment.
MetHoD
setting and sampling units
The study was conducted between the 1st and the 
14th of September 2014 as a retrospective analysis of 
case notes. Medical notes and treatment regimes for 
156 patients were reviewed from Oncology and Palliative 
Care Outpatients, Day Ward, Oncology Wards and the 
Palliative Care Unit. 
selection criteria
Inclusion criteria included adult oncology and 
palliative care patients who were prescribed, or had 
the intention of being prescribed dexamethasone or 
prednisolone for more than 2 weeks. Hyperglycaemia, 
dyspepsia, oral candidiasis and proximal myopathy were 
assessed due to their high prevalence in cancer patients, 
ease of management and monitoring.
The exclusion criteria included corticosteroids 
prescribed for short term intervals as adjuvant antiemetic 
with chemotherapy. Patients younger than 12 years of age 
were not included in the study. 
When considering such selection criteria, from the 
156 case notes that were reviewed only 55 qualified for 
the study, and hence had their case notes evaluated.
Measuring performance
Performance was measured from the time the patient 
was first prescribed steroids for a 2-week treatment 
duration or more.
Performance was measured in terms of:
(1) Clinical assessment for side effect detection,
(2) Clinical education to patient, and
(3) Clinical action in addressing the already manifested 
side effect
There are no locally established guidelines and hence 
the guidelines that were used were those stated in a 
paper entitled “A practical guide to the monitoring and 
management of the complications of systemic corticosteroid 
therapy” in the Allergy, Asthma and Clinical Immunology 
Journal (Liu et al., 2013).
A proforma sheet was produced for each of the side 
effects previously mentioned and filled in for every patient. 
Data was processed using Microsoft Excel 2013.
The performance was measured by comparing the 
management stated in the notes with that of the guidelines. 
Compliance was calculated as follows: the number of 
patients on whom an intervention was performed as per 
guidelines, divided by the total number of patients sampled 
(n=55) multiplied by 100%
Pilot study (10%)
A pilot study was undertaken 2 days prior to the 
2-week data retrieval period. Twenty case notes were 
reviewed of which 6 could be evaluated as they satisfied 
the selection criteria. The proforma for the 6 patients was 
effective in measuring performance without major bias. 
Hence no changes to the original proforma were made 
other than extending the retrieval time period from two 
days to a fourteen day time window.
ethical approval and consent
The study was approved by the Audit and the Data 
Protection Act committees. Consent was achieved from the 
Chairman of Oncology/Haematology and all oncologists at 
Sir Paul Boffa Hospital. The University Research and Ethics 
Committee was not involved as no human subjects were 
involved – only case notes were utilised for data retrieval.
results 
Corticosteroids were prescribed in 12 known primaries 
(n=54; 98%). Figure 1 shows the number of patients 
for each of the primary carcinomas to which a long term 
corticosteroid was prescribed. The main indications were 
for nerve pain, control in bone metastases and other 
metastases mainly of the lung and the liver. With regard 
to brain primaries, namely astrocytoma and glioblastoma, 
steroids were indicated due to the direct effect of the 
tumour on the intracranial pressure (n=5; 9%). Other 
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indications included decreased appetite (n=6; 11%) and 
emesis (n=2; 3.7%).
Dexamethasone and prednisolone were the only 
corticosteroids to be prescribed. Seventy-five per cent 
(n=41) of all patients were prescribed the former, with the 
2mg daily dose being the most prescribed regimen (n=14; 
34%). Figures 2a and 2b represent the corticosteroid 
doses. Treatment duration spanned from 2 weeks to 3 
and a half years (Figure 3), with 1 month being the most 
common treatment duration (n=20; 36%).
Table 1 indicated that the most addressed side effect 
was dyspepsia (n=35; 64%), followed by proximal 
myopathy (n=27; 49%), hyperglycaemia (n=24; 44%) 
and lastly oral candidiasis (n=20; 36%).
Although, for convenience sake, the management of 
each side effect was classified into clinical assessment, 
education and action (treatment) it is to be noted that the 
three interventions could all have been done individually 
or combined together in the same patient.
Management of hyperglycaemia
Hyperglycaemia was addressed in less than half of 
the patients (n=24; 44%). Such patients were managed 
as shown in Figure 4, where monotherapy was the 
mainstay of treatment. Haemo gluco testing (HGT) was 
the most common method used to address hyperglycaemia 
proactively (n=19; 35%).
Management of dyspepsia
Only a pro-active approach was implemented, 
mainly in the form of gastroprotective agents, of which 
omeprazole (n=28; 51 %) was preferred over ranitidine 
(n=3; 9%) and their combination (n=4; 11%) (Figure 5). 
Management of oral candidiasis
Oral candidiasis was mainly addressed pro-actively 
whereby oropharyngeal examination was the most 
common method (n=16; 29%) to be employed (Figure 6).
Management of proximal myopathy
Both clinical management and a proactive approach 
were given similar importance. As shown in Figure 7, 
assessment of lower limb power (n=21; 38%) and 
physiotherapy referral for quadriceps strengthening 
(n=19; 35%) were the commonest strategies 
employed.
Tables 2a and 2b provide a summarised comparative 
study, including percentage compliance, for each side 
effect.
DisCussion
the importance of long term steroid use in 
cancer patients
Corticosteroids are commonly used in the treatment 
of cancer, primarily owing to their anti-inflammatory 
activities (Rhen and Cidlowski, 2005). Recently it has 
been found that corticosteroids may have a direct effect 
on the modulation of tumour biology and angiogenesis 
as well as on tumour-associated pain (Dietrich et al., 
2011). Other benefits include limiting nausea and 
vomiting and improving appetite in cancer patients.
side effects related to long term steroid use
In a prospective study the most common side effects 
associated with corticosteroid use (at 10–30 mg/day of 
prednisolone and 4-16mg/day of dexamethasone) were 
oral candidiasis (26% with prednisolone, 37% with 
dexamethasone), oedema (18% prednisolone, 21% 
dexamethasone), cushingoid facies (15% prednisolone, 
21% dexamethasone), dyspepsia (8% prednisolone, 9% 
dexamethasone), and weight gain (4% prednisolone, 
5% dexamethasone) (Dorffl and Crawford, 2013). 
A separate study states that hyperglycaemia occurs 
in a majority of hospitalised patients receiving high 
doses of corticosteroids (Donihi et al., 2006). Table 3 
provides a summary of adverse effects associated with 
corticosteroid dose.
Side Effect
Management (%)
(n=55)
No management (%)
(n=55)
Hyperglycaemia 44 56
Dyspepsia 64 36
Oral Candidiasis 36 64
Proximal Myopathy 49 51
Table 1: Percentage of patients managed for corticosteroid side effects
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Guidelines Study Compliance
Proactive Approach
•	 Education about the classic signs 
and symptoms of hyperglycemia. 
•	 Monitoring of glycated 
haemoglobin, fasting plasma 
glucose, 2hr plasma glucose using 
a 75-g oral glucose tolerance test. 
•	 Blood glucose should be 
monitored within 8 hours of the 
first dose. And then at least 48 hrs 
after initiation of corticosteroid 
therapy, regardless of whether or 
not the patient is diabetic.
Clinical Management
•	 Management guidelines as 
in those with pre-established 
diabetes.
Proactive Approach
•	 Haemo glucose and glycated 
haemoglobin testing.
Clinical Management
•	 Dietary advice 
•	 Metformin 
•	 Insulatard 
•	 Actrapid  
•	 Metformin+Glicliazide 
+Actrapid
I f  < 1 5 m m o l / L -  m e t f o r m i n , 
sulphonureas, meglitinides or GLP-1 
agonists. Sulphonureas (single dose) for 
prednisolone regimens and glicliazide 
MR or glimepride for dexamethasone as 
this is longer acting.
If >15mmol/l insulin and metformin is 
recommended
•	 Steroid dose reduction leads to 
improvement
•	 Discontinuation usually leads to 
complete reversal
13%
36%
Table 2a: Percentage compliance with management guidelines for hyperglycaemia
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40%
Side effect Guidelines Study Compliance
Dyspepsia
Oral 
Condidiasis
Proximal 
Myopathy
Proactive Approach
•	 Use of proton pump inhibitors 
for gastrointestinal protection in 
corticosteroid users at high risk of 
gastrointestinal bleeding or peptic 
ulcers for example those on non-
steroidal anti-inflammatory drugs, 
cancer patients, history of ulcers or 
gastrointestinal bleeding, and those 
with serious comorbidities (i.e., 
advanced cancer)
Proactive Approach
•	 Use of omeprazole, 
ranitidine or their 
combination
Proactive Approach
•	 Early recognition of 
infections through 
oropharyngeal 
examination
•	 History taking
•	 Regular mouth hygiene 
Clinical management
•	 Miconazole or nysatin 
with or without the use 
of mouthwash
Proactive Approach
•	 Assessment of lower 
limb power and advice 
on the possibility of 
muscle weakness 
Clinical management
•	 Physiotherapy referral 
and quadriceps 
strengthening
Proactive Approach
•	 Early recognition of infections 
through oropharyngeal examination
Clinical Management
•	 Reduction or discontinuation of 
steroid use as soon as possible. 
•	 Resistance and endurance exercise
29%
51%
Table 2b: Percentage compliance with management guidelines for dyspepsia, oral candidiasis and proximal myopathy
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Table 3: Adverse effects associated with steroid dosage regimen (Hanks et al., 1983)
Adverse Effect Corticosteroid type and dose 
for adverse effects
Hyperglycemia Low-dose dexamethasone (0.5-2 mg/day)
Low-dose predmisone (10 mg/day)
Low-dose predmisone (10 mg/day)
Low-dose predmisone (10 mg/day)
Low-dose predmisone (10 mg/day)
Low-dose predmisone (10 mg/day)
Low-dose predmisone (10 mg/day)
Low-dose dexamethasone (0.5-2 mg/day)
Infection
Myopathy
Osteoporosis
Oedema
Weight gain
Dyspnoea
Cushingoid facies
Figure 1: Number of patients 
(n=55) that were prescribed long 
term corticosteroids for each of the 
diagnosed primary carcinomas
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Figure 3: Treatment duration (months) of corticosteroid therapy (n=55)
Figure 2a: Number of patients (n=41) that were 
prescribed dexamethasone by different doses
Figure 2b: Number of patients (n=14) that were 
prescribed prednisolone by different doses
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Figure 4: Management 
of hyperglycaemia (n=55)
Figure 5: Management 
of dyspepsia (n=55)
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Figure 7: Management 
of Proximal Myopathy (n=55)
Figure 6: Management of oral 
candidiasis (n=55)
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As described previously the indications of corticosteroid 
therapy require relatively potent corticosteroids with long 
term and high dose regimens. In this study the mostly 
prescribed steroid was dexamethasone (75%) at a dosage 
regimen of 2mg daily (34%) for 1 month (36%).
1. Hyperglycaemia
Glucocorticoids decrease glucose utilisation 
and increase hepatic glucose production, leading to 
hyperglycaemia; nonetheless the development of frank 
diabetes in a previously normal patient is uncommon 
(Moghadam-Kia and Werth, 2010). The effects of 
glucocorticoid administration on glucose levels are 
observed within hours of steroid exposure and appear to 
be dose dependent (Liu et al, 2013).
From the results of this study, less than half of the 
patients on long term steroids (43.6%) were managed for 
hyperglycaemia in any way. One reason for this might be 
that most of the steroid doses were not high enough to 
cause any concern among physicians. A less likely reason 
might also be that there was lack of awareness or lack of 
documentation among physicians.
Comparing to guidelines: proactive approach
Thirty-six per cent of patients were proactively 
managed according to guidelines only through HGT and 
HbA1c monitoring. No mention was made of whether the 
blood glucose levels were pre or post dose. Nonetheless 
there was no mention of any educational advice given with 
regards to the classic signs of hyperglycaemia. It is to be 
noted that educational advice could have been mentioned 
but not documented.
Comparing to guidelines: clinical management
Glycaemic targets for patients with corticosteroid-
induced diabetes should be individualised, but for most 
patients, fasting plasma glucose and 2-hour plasma 
glucose targets of 4.0-7.0 mmol/L and 5–10 mmol/L 
respectively, are recommended (Cheng et al, 2013).
Thirteen per cent of patients were actively managed 
according to guidelines but compliance of this was only 
partial as insulin and metformin were given only to patients 
who had pre-existing diabetes and not specifically to those 
with steroid induced diabetes of levels >15mmol/L. Thus 
oral hypoglycaemics, as monotherapy, were the mainstay 
of treatment in this case. Such management would have 
been improved if a referral to a multidisciplinary diabetes 
team was conducted (Liu et al, 2013).
None of the clinicians resorted to a decrease in steroid 
dose or discontinuation of treatment as suggested by the 
guidelines. This may have been due to the fact that the 
benefit of steroid use at a therapeutic level outweighed 
the risks of hyperglycaemia.
It can be said that more is desired with respect to 
proactive management as the tests done are minimally 
invasive, non time-consuming and reliable. From the 
clinicians’ point of view, awareness of glucose level cut-
off points and steroid pharmacokinetics is paramount for 
optimal pharmacological glucose control. Patients should 
always be made aware of the most common clinical signs 
of hyperglycaemia so that help is sought immediately as 
this would allow prompt action to be employed.
2. Dyspepisa
The use of systemic glucocorticoids is associated 
with gastrointestinal (GI) side effects including gastritis, 
peptic ulceration and gastrointestinal haemorrhage 
(Moghadam-Kia and Werth, 2010). Recent evidence 
suggests that the risk of peptic ulcer disease due to 
corticosteroid alone is low, but increases significantly 
when these agents are used in combination with non-
steroidal anti-inflammatory drugs (NSAIDs) (Hawkey & 
Longman, 2003). 
In this study, dyspepsia was found to be the side effect 
which physicians were mostly aware of. It was found that 
protection was mostly offered to those patients with a 
high risk of GI bleeding or peptic ulcers. As stated by 
Hawkey & Longman (2003), corticosteroids act only as 
an NSAID specific risk magnifier and hence this may 
give rise to the debate of whether corticosteroids on 
their own increase risk of gastritis. This lack of clarity in 
evidence-based material might explain the rationale why 
a gastro-protective agent was not commonly prescribed 
in patients that have no history of gastritis, ulceration 
or GI bleeding.
Comparing to guidelines: proactive approach
As per the guidelines, management was only in 
the proactive form, with omeprazole being the most 
commonly prescribed. When compared to H2 receptor 
antagonists, the proton pump inhibitors are a superior 
treatment modality for ulcer healing due to their ability 
to effectively control acid (Meijia and Kraft, 2009). 
No evidence based rationale was found that state that 
ranitidine and omeprazole combination therapy is more 
effective than omeprazole on its own. 
Physicians may also have opted more for 
omeprazole since its dosage form is in capsule 
form and hence easier to swallow than ranitidine. 
Another reason for prescribing omeprazole could  
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have the physicians’ awareness of the recommended 
prophylactic use of 20mg omeprazole in steroid 
induced ulcers (Lanza et al, 2009).
It is to be noted that patient advice with regards 
to lifestyle and steroid administration was not 
performed or not documented.
3. oral candidiasis
Corticosteroids have been shown to affect T-cells 
by inducing thymocyte apoptosis after polyclonal T-cell 
activation, leading to reduced function of the immune 
system (Herold, McPherson and Reichardt, 2006).
Owing to the immunosuppressive effects of 
corticosteroids, patients may be at increased risk for 
increased risk of topical bacterial and fungal infections 
(Systemic steroids, 2014).
Hence it can be said that prednisolone and 
dexamethasone doses of more than 10mg and 1.5mg 
respectively can lead to a significant risk of oral 
candidiasis (Poetker and Reh, 2010). 
The study shows that only 36% of patients on 
long term steroids where addressed for potential oral 
candidiasis, making it the least managed steroid induced 
side effect. Seventy-one per cent of patients of the same 
cohort were taking prednisolone or dexamethasone doses 
that were greater than 10mg and 0.5mg respectively and 
hence would have warranted a form of management 
(see Table 3). Reasons for this could be either failure of 
documentation or lack of clinicians’ awareness.
Comparing to guidelines: proactive approach
Compliance to guidelines was achieved in 29% 
of patients of whom an orophargyngeal exam was 
conducted prior to commencement of corticosteroid 
therapy. Reasons for physicians not performing an 
oropharyngeal examination may be lack of awareness 
or failure to document. Oral candidiasis is mainly 
diagnosed clinically and hence awareness among 
physicians to look for clinical signs during follow up or 
before increasing corticosteroid dose is essential. Other 
proactive management actions that were performed by 
the physicians but not mentioned in guidelines included 
mouth hygiene and further history taking.
Comparing to guidelines: clinical management
The guidelines do not specify any form of active 
management but the study indicated that 16 % of patients 
were prescribed either a mouth wash or a form of a topical 
antifungal. This lack of compliance may be due to the 
fact that the guidelines were not formulated specifically 
for cancer patients. As in this case, active management 
may be appropriate in immunosuppressants secondary 
to carcinomas (Liu et al., 2013), but routine primary 
prophylaxis is not recommended. However, if 
recurrences are frequent or severe, oral fluconazole 
can be used for either oropharyngeal or vulvovaginal 
candidiasis (Kaplan et al., 2009).
Initial episodes of oropharyngeal candidiasis can 
be adequately treated with topical therapy, including 
nystatin suspension or miconazole oral gel. Routine 
general advice about maintaining oral hygiene is always 
appropriate at any steroid regimen prescribed.
4. Proximal myopathy
Glucocorticoids have a direct catabolic effect on 
skeletal muscle (Sun et al., 2008). Onset of symptoms 
usually takes several weeks, and patients typically 
present with proximal muscle weakness and atrophy in 
both the upper and lower extremities (Moghadam-Kia 
and Werth, 2010).
It was found that half of the patients on long term 
steroids were managed for proximal myopathy. Lower 
limb power assessment, physiotherapy referrals and 
quadriceps strengthening were the most common 
forms of management respectively. Patient education 
was observed only in 5% of patients most probably 
because of failure in documentation. It is vital to 
clarify to the patient the fact that weakness is due 
to corticosteroid effect rather than due to cancer 
progression.
In those patients that were not managed, 
prednisolone doses were less than 10mg and the 
likelihood of side effect manifestation is very low. 
But 43 % of such patients were on average daily 
dexamethasone doses greater than 1.5mg (equivalent 
to 10mg prednisolone) - see Table 3. This means there 
may be lack of knowledge with regards to steroid dosing 
and proximal myopathy.
Comparing to guidelines
According to the guidelines only clinical 
management is to be considered. Compliance was 
mostly noted when it came to resistance and endurance 
exercises. Some literature suggests that aerobic 
exercises and resistance training may help to prevent 
weakness or reduce its severity (Foye, 2015).
A proactive approach, a low steroid dose, low 
potency or insufficient regimen duration for steroid-
induced myopathy may have reduced steroid 
manifestation and hence in practice this might have led 
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to less manifestations and hence less clinical management. 
Other possibilities for non-adherence may be lack of 
awareness and failure to document.
The main treatment recommendations for steroid 
myopathy are a decrease in the dose of steroid to 
below a threshold level or the discontinuation of the 
corticosteroid’s use. Alternate-day dosing could also be 
considered (Gupta and Gupta, 2013). But again reduction 
in steroid dose was an uncommon choice with physicians. 
Physicians may have opted out of this option as benefits 
of corticosteroid use may have outweighed the risks of 
proximal myopathy manifestation or worsening of the 
condition.
limitations
Many limitations were encountered in the study. 
Firstly, the guidelines to which the results were compared 
were not specifically formulated for cancer patients 
but for patients with inflammatory and immunological 
conditions that required long term systemic corticosteroid 
use. Due to time constraints only the most common 
clinically encountered side effects were considered. 
Osteoporosis, skin atrophy and psychiatric side effects 
were not assessed. Furthermore, although differences in 
monitoring and care exist between adults and children, 
only the adult population was sampled.
With regards to data collection, this was based only 
on what the clinicians had documented, and hence may 
not reliably reflect the actual intention of the prescriber. 
For example advice may have been given by the clinician 
but not necessarily documented.
Although the cancer type, steroid doses and duration 
of treatment were recorded, in view of time constraints, 
the effect of such steroid regimens on the manifestation of 
type and severity of side effect were not evaluated. It was 
also assumed that the side effects were purely long-term 
corticosteroid induced and not affected by other causes, 
e.g. comorbidities (cancer), drug interaction, etc.
recommendations
This study has shown that hyperglycaemia, oral 
candidiasis, heartburn and proximal myopathy may often 
be overlooked in cancer patients who are on long-term 
steroids. If proactive and / or active management is to be 
provided, it is vital that patient assessment, education 
and appropriate treatment is sought.
From the study several recommendations can be 
highlighted that would help to improve the management 
of steroid side effects. Firstly, awareness amongst 
physicians of the above-mentioned guidelines is essential 
if they are to be followed and applied accordingly. These 
should be clear, regularly updated, well disseminated 
and enforced. One practical way to ensure this would 
be to make these management guidelines available on 
Mater Dei’s Intranet (Kura) were they can be clear, easy 
to use regularly updated. Regular audits, the availability 
of hard copies on the wards and education campaigns are 
other ways by which awareness can be increased among 
prescribers.
Secondly, from the prescribers’ side, documentation 
of any signs of corticosteroid side effects in medical 
notes is vital as their presence may affect the patient’s 
management plan. This will also help when reviewing 
corticosteroid doses on weekly bases. Dexamethasone 
should be given as single morning dose, or if a higher 
dose needed give in 2 divided doses, the second being no 
later than 2 p.m. to minimise risk of sleep disturbance.
Thirdly, patients should be informed about the 
common corticosteroid side effects and advised on 
lifestyle modification strategies that may help reduce the 
risk of these events. If discharged home, the physician 
should instruct patients to seek medical advice in the case 
corticosteroid side effect manifestations (Princess Alice 
Hospice Guidelines for corticosteroid use in palliative 
care, 2008).
Patients on systemic steroids for >3 weeks must 
be given a steroid card so that it can be shown to all 
healthcare professionals involved in their care and 
management (North of England Cancer Network palliative 
care guidelines, 2013). This should include the indication 
for steroid use and the plan for dose reduction and 
monitoring. At end of life, if corticosteroids are prescribed 
for specific severe or serious symptom, these should be 
continued at the most convenient subcutaneous dose. If 
prescribed for ‘general well-being’ or appetite stimulation 
they should be discontinued.
The provision of educational leaflets may facilitate 
delivery of information to patients as well as save the 
clinician’s time. Furthermore, the assistance of allied 
health care professionals in the clinical assessment and 
education prior to the patient’s consultation with the 
physician may assist in the awareness of corticosteroid 
side effects.
ConClusion
Much has still to be done in order to implement 
management as proposed by guidelines for steroid 
induced side effects, especially when it comes to treatment 
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and prevention of steroid induced hyperglycaemia and 
oral candidiasis. These adverse effects are particularly 
important as they tend to be more severe and commoner 
in cancer patients than in the rest of the population. 
Management should involve more careful patient 
monitoring and implementation of preventive measures, 
including the use of lower potency agents and the lowest 
effective dose required for management of the underlying 
condition. Management should also involve the treatment 
of the manifested side effects as well.
Furthermore, patients should be informed more about 
the side effects associated with systemic corticosteroid 
use and should be advised on lifestyle modification 
strategies that may help reduce the risk of these events. 
Patients should also be instructed to seek medical 
attention if they experience signs and symptoms of 
steroid-related side effects and should also be advised 
to carry a steroid treatment card that can be shown to 
all healthcare professionals involved in their care and 
management. Differences in the monitoring and care of 
adults versus children should also be noted.
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